McKesson Corp (MCK) stock
MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3026% above fair value
$1102.81+25.76 (+2.39%)
Close on Nov 13, 2026Market cap $128.58BP/E 28.4Yield 0.29%
McKesson r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2020 it was $96.00M, up 35.2% from the year before. Over ten years it grew -12.8% a year on average. The highest annual figure on record is $457.00M in fiscal 2014.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Mar 31, 2020 | $96.00M | +35.2% |
| FY2019 | Mar 31, 2019 | $71.00M | -43.2% |
| FY2018 | Mar 31, 2018 | $125.00M | -63.3% |
| FY2017 | Mar 31, 2017 | $341.00M | -13.0% |
| FY2016 | Mar 31, 2016 | $392.00M | 0.0% |
| FY2015 | Mar 31, 2015 | $392.00M | -14.2% |
| FY2014 | Mar 31, 2014 | $457.00M | +5.5% |
| FY2013 | Mar 31, 2013 | $433.00M | +7.7% |
| FY2012 | Mar 31, 2012 | $402.00M | -1.2% |
| FY2011 | Mar 31, 2011 | $407.00M | +8.2% |
| FY2010 | Mar 31, 2010 | $376.00M | +3.3% |
| FY2009 | Mar 31, 2009 | $364.00M | +4.9% |
| FY2008 | Mar 31, 2008 | $347.00M | – |
See a number that looks wrong?